A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Status:
RECRUITING
Trial end date:
2027-05-19
Target enrollment:
Participant gender:
Summary
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University